The present invention provides prodrugs of selective androgen receptor
modulators (SARMs), and their use in treating or reducing the incidence
of osteoporosis, a variety of hormone-related conditions, conditions
associated with Androgen Decline in Aging Male (ADAM); conditions
associated with Androgen Decline in Female (ADIF), and muscular wasting
conditions, obesity, dry eye conditions, and prostate cancer. The
prodrugs are also useful in oral androgen replacement therapy and male
contraception.